newsfilter
← Latest News
Business Wire·

Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

LP352 Phase 1b/2a PACIFIC Study enrollment completion expected this summer with topline data expected around year-end 2023 Ended second quarter 2023 with $63.0 million in cash, cash equivalents and investments; cash